Loading company
$1.740.0%Nov 6 close
Figures through June 30, 2026, from the 10-Q filed August 13, 2026
Past performance
- 1M
- 0.0%
- 3M
- -43.9%
- 6M
- -59.4%
- 1Y
- -95.6%
- 5Y
- -99.9%
$1.740.0%Nov 6 close
Figures through June 30, 2026, from the 10-Q filed August 13, 2026
The quarter ending September 30, 2023, against the same quarter a year earlier.
| Measure | 3 months toSep 30, 2023 | 3 months toJun 30, 2022 | Change |
|---|---|---|---|
| Total Revenue | $0.00 | $0.00 | — |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“As we evaluate strategic paths forward, our focus remains on supporting the advancement of the ongoing Phase 1 study of BA3182 in adenocarcinomas, while preserving capital, and ensuring we maintain the flexibility to pursue all potential value-creating options,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
(CAB-EpCAM x CAB-CD3 Bispecific T-cell Engager Antibody) BioAtla is developing BA3182 as a potential anticancer therapy for patients with advanced adenocarcinoma. BA3182 is a (CAB) EpCAM x (CAB) CD3 bispecific T cell engager antibody with binding sites for EpCAM and CD3ε designed to bind their respective targets specifically and reversibly under the conditions found in the tumor microenvironment (TME) and to have reduced binding outside of the TME. The CAB selective binding to both the CAB EpCAM and CAB CD3ε arms are required to activate the T cell engagement against the tumor, thus enabling the combined selectivity of each CAB binding arm in the bispecific antibody. BioAtla continues to advance the ongoing Phase 1 study to evaluate the safety, pharmacokinetics, and efficacy of BA3182 in advanced adenocarcinoma patients.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from BioAtla, Inc.’s Item 2.02 8-K filed March 31, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
BioAtla, Inc. has no earnings call transcript available.